ELABORATION AND USE OF SYNGENIC PRE-CLINICAL MODELS FOR CANCER DRUG DEVELOPMENT

癌症药物开发同源临床前模型的阐述和使用

• 批准号: 10502661
• 负责人: ETHAN DMITROVSKY
• 金额: $ 1214.94万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-16 至 2026-09-15
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10502661
• 关键词: Animals; Antineoplastic Agents; Biological Models; Development; Division of Cancer Treatment and Diagnosis; Immune system; Immunocompromised Host; Immunooncology; Pre-Clinical Model; Xenograft Model; drug development; evaluation/testing; interest; preclinical evaluation

The Division of Cancer Treatment and Diagnosis, NCI is requesting support for the development and/or use of existing syngeneic model systems for the pre-clinical evaluation and testing of anti-cancer agents in the presence of an intact immune system. This is of particular interest for immuno-oncology (I/O) agents which cannot be evaluated in the standard xenograft model systems requiring the use of immunocompromised animals.

NCI癌症治疗和诊断部门正在寻求支持，开发和/或使用现有的同基因模型系统，用于在完整免疫系统存在的情况下对抗癌药物进行临床前评估和测试。这对免疫肿瘤学（I/O）药物特别有意义，因为它们不能在需要使用免疫功能低下动物的标准异种移植模型系统中进行评估。